WO2021075691A1 - Dérivé de pyrimidine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que composant actif - Google Patents
Dérivé de pyrimidine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que composant actif Download PDFInfo
- Publication number
- WO2021075691A1 WO2021075691A1 PCT/KR2020/010657 KR2020010657W WO2021075691A1 WO 2021075691 A1 WO2021075691 A1 WO 2021075691A1 KR 2020010657 W KR2020010657 W KR 2020010657W WO 2021075691 A1 WO2021075691 A1 WO 2021075691A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- amino
- egfr
- phenyl
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 57
- 201000011510 cancer Diseases 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 19
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 11
- 230000035772 mutation Effects 0.000 claims abstract description 62
- 102000001301 EGF receptor Human genes 0.000 claims description 120
- 108060006698 EGF receptor Proteins 0.000 claims description 120
- 150000001875 compounds Chemical class 0.000 claims description 86
- -1 2-(methylsulfonamido)phenyl Chemical group 0.000 claims description 52
- 102200048955 rs121434569 Human genes 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 37
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 31
- 102200048928 rs121434568 Human genes 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 102220052594 rs1554350347 Human genes 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 201000009036 biliary tract cancer Diseases 0.000 claims description 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- POUHCLFSUMDRNT-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCC(CC1)N(C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCC(CC1)N(C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C POUHCLFSUMDRNT-UHFFFAOYSA-N 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 4
- 208000020615 rectal carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- TYTNAGJIJPGMND-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCN(CC1)C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCN(CC1)C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C TYTNAGJIJPGMND-UHFFFAOYSA-N 0.000 claims description 3
- OVNCIZYHBGQGBY-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCOCC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCOCC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C OVNCIZYHBGQGBY-UHFFFAOYSA-N 0.000 claims description 3
- IFZIUGOINXJLKW-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCC(CC1)N1CCN(CC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCC(CC1)N1CCN(CC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C IFZIUGOINXJLKW-UHFFFAOYSA-N 0.000 claims description 3
- ISGYTNMQZLVUGZ-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCN(CC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCN(CC1)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C ISGYTNMQZLVUGZ-UHFFFAOYSA-N 0.000 claims description 3
- WGOSZNNEJWVZKJ-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCOCC1)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N1CCOCC1)OC)NC1=C(C=CC=C1)NS(=O)(=O)C WGOSZNNEJWVZKJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010061825 Duodenal neoplasm Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 3
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 206010054184 Small intestine carcinoma Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 206010044002 Tonsil cancer Diseases 0.000 claims description 3
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010009259 cleft lip Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000000312 duodenum cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 208000010749 gastric carcinoma Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000011587 gastric lymphoma Diseases 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010235 heart cancer Diseases 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000006359 hepatoblastoma Diseases 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 201000003175 male breast cancer Diseases 0.000 claims description 3
- 208000010907 male breast carcinoma Diseases 0.000 claims description 3
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 201000000349 mediastinal cancer Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000009612 pediatric lymphoma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 201000003437 pleural cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 208000037968 sinus cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011096 spinal cancer Diseases 0.000 claims description 3
- 208000014618 spinal cord cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- DKJFPTTZFVALMH-UHFFFAOYSA-N ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(C)CCN(C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C Chemical compound ClC=1C(=NC(=NC1)NC=1C(=CC(=C(C1)NC(C=C)=O)N(C)CCN(C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)C DKJFPTTZFVALMH-UHFFFAOYSA-N 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 150000003018 phosphorus compounds Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 14
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000010261 cell growth Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229960003278 osimertinib Drugs 0.000 description 11
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 229940121647 egfr inhibitor Drugs 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102220436265 rs1554350337 Human genes 0.000 description 6
- 102220014448 rs1554350381 Human genes 0.000 description 6
- 102220014441 rs397517109 Human genes 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- KPUXYKMAEDAWET-UHFFFAOYSA-N C1=C(C(=CC(=C1OC)NC(=O)OC(C)(C)C)N(=O)=O)F Chemical compound C1=C(C(=CC(=C1OC)NC(=O)OC(C)(C)C)N(=O)=O)F KPUXYKMAEDAWET-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000012054 celltiter-glo Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- YLNRCLFODARCHN-UHFFFAOYSA-N n-[2-[(2,5-dichloropyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl YLNRCLFODARCHN-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- ZDHUOHXJOTTYGN-UHFFFAOYSA-N 2,5-dichloro-N-(2-nitrophenyl)pyrimidin-4-amine Chemical compound C1(Cl)=C(NC2=C(N(=O)=O)C=CC=C2)N=C(N=C1)Cl ZDHUOHXJOTTYGN-UHFFFAOYSA-N 0.000 description 3
- IOUSSSXSMQFGSU-UHFFFAOYSA-N 2-n-(2,5-dichloropyrimidin-4-yl)benzene-1,2-diamine Chemical compound NC1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl IOUSSSXSMQFGSU-UHFFFAOYSA-N 0.000 description 3
- FYSIGSQCZXQTIH-UHFFFAOYSA-N 4-fluoro-2-methoxy-5-nitroaniline Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1N FYSIGSQCZXQTIH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GPEOSDIKTVSDHN-UHFFFAOYSA-N C(CN(C)C)N(C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1N(=O)=O)C Chemical compound C(CN(C)C)N(C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1N(=O)=O)C GPEOSDIKTVSDHN-UHFFFAOYSA-N 0.000 description 3
- FKHBXDRZYHNBLX-UHFFFAOYSA-N COC1=C(NC(=O)OC(C)(C)C)C=C(NC(=O)C=C)C(=C1)N1CCC(CC1)N(C)C Chemical compound COC1=C(NC(=O)OC(C)(C)C)C=C(NC(=O)C=C)C(=C1)N1CCC(CC1)N(C)C FKHBXDRZYHNBLX-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UXTORUSZNFZEPZ-UHFFFAOYSA-N N(C)(CCN(C)C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1N)C Chemical compound N(C)(CCN(C)C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1N)C UXTORUSZNFZEPZ-UHFFFAOYSA-N 0.000 description 3
- AHKADPGTHXIDQX-UHFFFAOYSA-N N(CCN(C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1NC(=O)C=C)C)(C)C Chemical compound N(CCN(C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1NC(=O)C=C)C)(C)C AHKADPGTHXIDQX-UHFFFAOYSA-N 0.000 description 3
- MFNDJPOYVIUUBT-UHFFFAOYSA-N NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC Chemical compound NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC MFNDJPOYVIUUBT-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102220055958 rs727504263 Human genes 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JJQWXKFQGZWBJE-UHFFFAOYSA-N C1CN(CCN1C)C1=CC(OC)=C(N)C=C1NC(=O)C=C Chemical compound C1CN(CCN1C)C1=CC(OC)=C(N)C=C1NC(=O)C=C JJQWXKFQGZWBJE-UHFFFAOYSA-N 0.000 description 2
- OIDHIEBTJGUEJE-UHFFFAOYSA-N CN(C)CCOC1=C(C=C(C(=C1)OC)NC2=NC=C(C(=N2)NC3=CC=CC=C3NS(=O)(=O)C)Cl)NC(=O)C=C Chemical compound CN(C)CCOC1=C(C=C(C(=C1)OC)NC2=NC=C(C(=N2)NC3=CC=CC=C3NS(=O)(=O)C)Cl)NC(=O)C=C OIDHIEBTJGUEJE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- URVVVMUZLBJMOM-UHFFFAOYSA-N N(C)(C1CCN(CC1)C1=CC(OC)=C(N)C=C1NC(=O)C=C)C Chemical compound N(C)(C1CCN(CC1)C1=CC(OC)=C(N)C=C1NC(=O)C=C)C URVVVMUZLBJMOM-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- QJDVRSWQZWVVQW-UHFFFAOYSA-N N-[5-amino-2-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]prop-2-enamide Chemical compound N(C)(C)CCOC1=CC(OC)=C(N)C=C1NC(=O)C=C QJDVRSWQZWVVQW-UHFFFAOYSA-N 0.000 description 2
- LVEOSWMNFRFDBE-UHFFFAOYSA-N N-[5-amino-4-methoxy-2-(2-morpholin-4-ylethoxy)phenyl]prop-2-enamide Chemical compound NC=1C(=CC(=C(C1)NC(C=C)=O)OCCN1CCOCC1)OC LVEOSWMNFRFDBE-UHFFFAOYSA-N 0.000 description 2
- RWPZPXNEYXGGCD-UHFFFAOYSA-N NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCOCC1)C)OC Chemical compound NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCOCC1)C)OC RWPZPXNEYXGGCD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- ZSHQRQVIIJMPES-UHFFFAOYSA-N tert-butyl N-[4-[2-(dimethylamino)ethoxy]-2-methoxy-5-(prop-2-enoylamino)phenyl]carbamate Chemical compound N(C)(CCOC1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1NC(=O)C=C)C ZSHQRQVIIJMPES-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940071104 xylenesulfonate Drugs 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- MRYYJGQKVGZGSB-UHFFFAOYSA-N 1-methyl-4-piperidin-4-ylpiperazine Chemical compound C1CN(C)CCN1C1CCNCC1 MRYYJGQKVGZGSB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BNRRMRUVYDETQC-UHFFFAOYSA-N 4-fluoro-2-methoxyaniline Chemical compound COC1=CC(F)=CC=C1N BNRRMRUVYDETQC-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- SSRNQDAVLFANAV-UHFFFAOYSA-N C(C=C)(=O)NC=1C(=CC(=C(C1)NC(OC(C)(C)C)=O)OC)N(CCN1CCN(CC1)C)C Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C1)NC(OC(C)(C)C)=O)OC)N(CCN1CCN(CC1)C)C SSRNQDAVLFANAV-UHFFFAOYSA-N 0.000 description 1
- ZJHWLMVPGLUMBL-UHFFFAOYSA-N C(C=C)(=O)NC=1C(=CC(=C(C1)NC(OC(C)(C)C)=O)OC)N(CCN1CCOCC1)C Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C1)NC(OC(C)(C)C)=O)OC)N(CCN1CCOCC1)C ZJHWLMVPGLUMBL-UHFFFAOYSA-N 0.000 description 1
- WJNJWARKGCEAOC-UHFFFAOYSA-N CC(C)N(C)CCN1CCN(C)CC1 Chemical compound CC(C)N(C)CCN1CCN(C)CC1 WJNJWARKGCEAOC-UHFFFAOYSA-N 0.000 description 1
- XLZMWNWNBXSZKF-UHFFFAOYSA-N CC(C)N1CCOCC1 Chemical compound CC(C)N1CCOCC1 XLZMWNWNBXSZKF-UHFFFAOYSA-N 0.000 description 1
- LHQQTYKFQXHPGT-UHFFFAOYSA-N COc(cc(c(NC(C=C)=O)c1)OCCN2CCOCC2)c1Nc(nc1)nc(Nc(cccc2)c2NS(C)(=O)=O)c1Cl Chemical compound COc(cc(c(NC(C=C)=O)c1)OCCN2CCOCC2)c1Nc(nc1)nc(Nc(cccc2)c2NS(C)(=O)=O)c1Cl LHQQTYKFQXHPGT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- FSIHXTUJIBLKEA-UHFFFAOYSA-N N-[5-amino-4-methoxy-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]prop-2-enamide Chemical compound COc1cc(N2CCC(CC2)N2CCN(C)CC2)c(NC(=O)C=C)cc1N FSIHXTUJIBLKEA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- WPJYWAQXINSPQD-UHFFFAOYSA-N NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCN(CC1)C)C)OC Chemical compound NC=1C(=CC(=C(C1)NC(C=C)=O)N(CCN1CCN(CC1)C)C)OC WPJYWAQXINSPQD-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- LZEBHQQBLHMJOG-UHFFFAOYSA-N n-methyl-2-(4-methylpiperazin-1-yl)ethanamine Chemical compound CNCCN1CCN(C)CC1 LZEBHQQBLHMJOG-UHFFFAOYSA-N 0.000 description 1
- WWXPJKGWWPWBTB-UHFFFAOYSA-N n-methyl-2-morpholin-4-ylethanamine Chemical compound CNCCN1CCOCC1 WWXPJKGWWPWBTB-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- CBXHLPWBEBYYFY-UHFFFAOYSA-N tert-butyl N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(prop-2-enoylamino)phenyl]carbamate Chemical compound C1CN(CCN1C)C1=CC(OC)=C(NC(=O)OC(C)(C)C)C=C1NC(=O)C=C CBXHLPWBEBYYFY-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Definitions
- the present invention relates to a pharmaceutical composition for preventing or treating cancer, and specifically to a pharmaceutical composition for preventing or treating cancer containing a pyrimidine derivative as an active ingredient.
- Cancer incidence is related to changes in various environmental factors including chemicals, radiation, and viruses, oncogenes, tumor suppressor genes, and genes related to apoptosis and DNA repair.
- a new treatment, targeted chemotherapy became possible.
- Targeted therapies are generally made to target molecules characteristic of cancer cells to exert their effects, and molecular targets are cancer cell signal transduction pathways, angiogenesis, and interstitial cells. They are genes related to (matrix), cell cycle regulator, and apoptosis.
- Currently used as important target therapeutics in treatment include tyrosine kinase inhibitors, signaling pathway inhibitors, and angiogenesis inhibitors.
- EGFR epidermal growth factor receptor
- a receptor tyrosine kinase of the erbB family is a non-small cell lung cancer. It is abnormally activated in many epithelial cell tumors, including NSCLC, breast cancer, glioma, squamous cell carcinoma of the head and neck, colon cancer, rectal carcinoma, head and neck cancer, gastric cancer, and prostate cancer. It has been known that activation causes continuous cell proliferation, invasion of surrounding tissues, distant metastasis, and blood vessel formation, and increases cell survival.
- the EGFR is one of the ErbB tyrosine kinase receptors family (EGFR, HER-2, ErbB-3, ErbB-4), an extracelluar ligand-binding domain and a tyrosine kinase region It is a transmembrane tyrosine kinase that has an intracellular domain including (tyrosine kinase domain).
- PI3K phosphatidylinositol 3-kinase
- EGFR is overexpressed in more than half of non-small cell lung cancer (NSCLC), and many studies have been conducted as a target of treatment.
- EGFR TKI tyrosine kinase inhibitor
- representative drugs include gefitinib (IRESSATM), erlotinib (TARCEVATM), and lapatinib (TYKERBTM, TYVERBTM).
- the EGFR mutation is largely classified into a sensitizing mutation and a resistant mutation.
- the deletion of exon 19 and the L858R point mutation of exon 21 are the most important sensitive mutations. %, and exon 19 del mutations are known to be more sensitive to TKI.
- the T790M point mutation of exon 20 is the most important resistance mutation and is known to be found in more than 50% of acquired resistance patients (Clin Cancer Res 2006;12:6494-6501.).
- Somatic mutations identified so far include in-frame deletions within exon 19 or insertions in exon 20, as well as point mutations in which a single nucleic acid residue is modified in the expressed protein (e.g., L858R, G719S, G719C, G719A, L861Q) ( Fukuoka et al. JCO 2003; Kris et al JAMA 2003 and Shepherd et al NEJM 2004).
- EGFR mutations EGFR_del19 or EGFR_L858R
- their therapeutic drugs Iressa and Taseba
- Iressa and Taseba their therapeutic drugs
- Iressa and Taseba their therapeutic drugs
- this is the main cause of actual drug resistance.
- the first generation EGFR inhibitor is used for an average of 10 months, the acquired resistance of the T790M mutation located at the gatekeeper of the EGFR kinase occurs, and the first generation EGFR inhibitors do not take effect.
- EGFR_del19_T790M or EGFR_L858R_T790M double mutation occurs, preventing the existing treatment from showing efficacy.
- EGFR Exon20insertion mutations There is a wide variety of EGFR Exon20insertion mutations, including EGFR D770delinsGY, EGFR H773_V774insH, EGFR Y764_V765insHH, EGFR D770insASV and EGFR D770_N771insSVD.
- the pyrimidine derivatives according to the present invention exhibit relatively low inhibition against wild-type EGFR, while exhibiting high inhibitory ability against EGFR mutations, thereby preventing cancer.
- the present invention was completed by finding that it can be usefully used for treatment.
- Another object of the present invention is to provide a method for preparing the pyrimidine derivative.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer containing the pyrimidine derivative, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- Another object of the present invention is to provide a health functional food composition for preventing or improving cancer containing the pyrimidine derivative, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diseases related to EGFR mutations containing the pyrimidine derivative, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- R is -OR a or -NR b1 R b2 ,
- R a is -(CH 2 ) m -NR b1 R b2 , where m is 1 to 3,
- R b1 and R b2 are each independently hydrogen or unsubstituted or straight or branched chain C 1-6 alkyl substituted with NR c1 R c2 , or R b1 and R b2 are N, O together with the nitrogen to which they are attached. And to form an unsubstituted or straight or branched chain C 1-6 alkyl containing one or more heteroatoms selected from the group consisting of S or a 5 to 7 membered heterocycloalkyl substituted with NR c1 R c2,
- R c1 and R c2 are each independently hydrogen or straight or branched chain C 1-6 alkyl, or, R c1 and R c2 are selected from the group consisting of N, O and S together with the nitrogen to which they are attached. 5 to 7 membered heterocycloalkyl substituted with unsubstituted or straight or branched C 1-6 alkyl containing one or more atoms.
- R is as defined in Chemical Formula 1.
- a pharmaceutical composition for preventing or treating cancer containing the compound represented by Chemical Formula 1, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- a health functional food for preventing or improving cancer containing the compound represented by Formula 1, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- a pharmaceutical composition for preventing or treating diseases related to EGFR mutations containing the compound represented by Formula 1, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- cancer or EGFR comprising administering to a subject in need a pharmaceutical composition or a dietary supplement composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient It provides a method of preventing or treating mutation-related diseases.
- a pharmaceutical composition or a dietary supplement composition containing a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof in the prevention or treatment of cancer or EGFR mutation-related diseases Provides.
- the pyrimidine derivative according to the present invention exhibits a relatively weak inhibitory effect on EGFR activity against wild-type EGFR, and exhibits a high inhibitory ability against EGFR mutations, so it can be usefully used in the treatment of cancer in which EGFR mutations have occurred.
- 1 is a graph showing the results of measuring the cell growth inhibitory ability of the existing EGFR TKI (tyrosine kinase inhibitor) drug osimertinib against the Ba/F3 EGFR exon20 insertion mutation.
- EGFR TKI tyrosine kinase inhibitor
- Example 2 is a graph showing the results of measuring the cell growth inhibitory ability of the compound represented by Example 1 against the Ba/F3 EGFR exon20 insertion mutation.
- the present invention provides a compound represented by the following formula (1), an isomer thereof, or a pharmaceutically acceptable salt thereof.
- R is -OR a or -NR b1 R b2 ,
- R a is -(CH 2 ) m -NR b1 R b2 , where m is 1 to 3,
- R b1 and R b2 are each independently hydrogen or unsubstituted or straight or branched chain C 1-6 alkyl substituted with NR c1 R c2 , or R b1 and R b2 are N, O together with the nitrogen to which they are attached. And to form an unsubstituted or straight or branched chain C 1-6 alkyl containing one or more heteroatoms selected from the group consisting of S or a 5 to 7 membered heterocycloalkyl substituted with NR c1 R c2,
- R c1 and R c2 are each independently hydrogen or straight or branched chain C 1-6 alkyl, or, R c1 and R c2 are selected from the group consisting of N, O and S together with the nitrogen to which they are attached. 5 to 7 membered heterocycloalkyl substituted with unsubstituted or straight or branched C 1-6 alkyl containing one or more atoms.
- R is , , , , , , or Can be
- Examples of the compound represented by Formula 1 according to the present invention include the following compounds:
- the compound represented by Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful.
- Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid, etc., aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes.
- non-toxic organic acids such as dioate, aromatic acids, aliphatic and aromatic sulfonic acids, etc., acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, and the like.
- pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, i.
- the acid addition salt according to the present invention can be prepared by a conventional method, for example, a precipitate formed by dissolving the derivative of Formula 1 in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc. and adding an organic or inorganic acid It can be prepared by filtration and drying, or it can be prepared by distilling a solvent and an excess of acid under reduced pressure and then drying to crystallize under an organic solvent.
- an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc.
- a pharmaceutically acceptable metal salt can be made using a base.
- the alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt.
- the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable negative salt (eg, silver nitrate).
- the present invention includes not only the compound represented by Formula 1 and its pharmaceutically acceptable salts, but also solvates, isomers, hydrates, etc. that may be prepared therefrom.
- solvate refers to a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.
- Preferred solvents therefor include volatile, non-toxic, and/or suitable solvents for administration to humans. In this case, when the solvent is water, it is referred to as "hydrate”.
- isomers refers to a compound of the present invention or a salt thereof having the same chemical formula or molecular formula, but structurally or sterically different.
- isomers include structural isomers such as tautomers, R or S isomers having an asymmetric carbon center, stereoisomers such as geometric isomers (trans, cis), and optical isomers. All these isomers and mixtures thereof are also included within the scope of the present invention.
- It provides a method for preparing a compound represented by Formula 1, comprising the step of preparing a compound represented by Formula 1 by reacting a compound represented by Formula 2 with a compound represented by Formula 3.
- R is as defined in Chemical Formula 1.
- step 1 is a step of preparing a compound represented by Formula 1 by reacting a compound represented by Formula 2 with a compound represented by Formula 3. Specifically, this is a step in which the compound represented by Formula 1 is formed by reacting the halogen of the compound represented by Formula 2 with the primary amine of the compound represented by Formula 3.
- the reaction of Scheme 1 is not particularly limited as long as it is a condition capable of forming an amine bond by combining a halogen and an amine.
- an acid condition was used, and trifluoroacetic acid (TFA) was used as the acid, but the present invention is not limited thereto.
- the concentration of the acid may be 1 N, but is not limited thereto.
- the solvent usable in Reaction Scheme 1 is not particularly limited, but lower alcohols including isopropanol, methanol, ethanol, propanol and butanol; Tetrahydrofuran (THF); Dioxane; Ether solvents including ethyl ether and 1,2-dimethoxyethane; Dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonase sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenyl acetate, phenyl propionate , Phenylbutyrate, Cycrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, na
- reaction temperature in Scheme 1 may be 80° C. to 95° C., but is not limited thereto, and the reaction temperature may be appropriately adjusted according to the degree to which the reaction proceeds.
- reaction time in Scheme 1 may be 10 minutes to 24 hours, but is not limited thereto, and the reaction time may be appropriately adjusted according to the degree to which the reaction proceeds.
- the present invention provides a pharmaceutical composition for preventing or treating cancer containing the compound represented by Formula 1, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- the cancer is pseudomyxoma, intrahepatic biliary tract cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, cleft lip cancer, mycological sarcoma, acute myeloid leukemia, acute lymphocytic leukemia, basal cell Cancer, ovarian epithelial cancer, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colon cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, barter bulge cancer, bladder cancer, Peritoneal cancer, parathyroid cancer, adrenal cancer, non-sinus cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer
- the EGFR mutations are EGFR del19, EGFR L858R, EGFR del19/T790M, EGFR L858R/T790M, EGFR del19/T790M/C797S, EGFR L858R/T790M/C797S, EGFR D770delinsGY, EGFR H773_V774ins D770ASH, EGFR EGFR and EGFR D770ASH, EGFR and EGFR D770ASH, EGFR, and EGFR del19/T790M_EGFR L858R/T790M It may be one or more selected from the group consisting of.
- the compound represented by Formula 1 of the present invention exhibits a relatively weak inhibitory effect on EGFR activity against wild-type EGFR, while selectively exhibiting a high inhibitory ability against EGFR mutations, and in particular, exhibits a high inhibitory ability against EGFR del19/T790M, a double mutation. (See Experimental Example 1 and Table 2).
- the compound represented by Formula 1 of the present invention exhibits a selectively high cell growth inhibitory ability against EGFR mutations in Ba/F3 cell lines.
- the existing EGFR against triple mutations EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S Since it exhibits a higher cell growth inhibitory ability than Osimertinib, which is a tyrosine kinase inhibitor (TKI) drug, it can be seen that it exhibits superior anticancer effects than osimertinib (see Experimental Example 2, Table 3 and Table 4).
- TKI tyrosine kinase inhibitor
- Example 1 compound of the present invention selectively shows high cell growth inhibitory ability against EGFR mutations in Ba/F3 cell lines, specifically EGFR D770delinsGY, EGFR H773_V774insH, EGFR Y764_V765insHH, EGFR D770insASV or EGFR D770_N771insSVD Since it exhibits a higher cell growth inhibitory ability than mertinib, it can be seen that it exhibits superior anticancer effects than osimertinib (see Experimental Example 3 and Table 5).
- the compound represented by Formula 1 according to the present invention exhibits high inhibitory ability against EGFR mutations, EGFR del19, EGFR L858R, EGFR del19/T790M, EGFR L858R/T790M, EGFR del19/T790M/C797S, EGFR L858R/ T790M/C797S, EGFR D770delinsGY, EGFR H773_V774insH, EGFR Y764_V765insHH, EGFR D770insASV, EGFR D770_N771insSVD can be usefully used in the treatment of cancers expressing EGFR mutations.
- the inhibitory ability against T790M/C797S is remarkably excellent, it can be usefully used in the treatment of cancers expressing EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may be administered in various oral and parenteral formulations upon clinical administration.
- formulation it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc., but may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents. have.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, and emulsions.
- the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- a pharmaceutical composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient can be administered parenterally, and parenteral administration is by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. It depends on how to do it.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is mixed in water together with a stabilizer or buffer to prepare a solution or suspension, and the ampoule or vial unit dosage form It can be manufactured with.
- the composition may be sterilized and/or contain adjuvants such as preservatives, stabilizers, hydrating agents or emulsification accelerators, salts and/or buffers for controlling osmotic pressure, and other therapeutically useful substances, which are conventional methods of mixing and granulation. It can be formulated according to the method of painting or coating.
- Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, solutions, suspensions, emulsifiers, syrups, granules, elixirs, and troches. , Dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), lubricants (such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol). Tablets may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases boron such as starch, agar, alginic acid or sodium salt thereof. It may contain release or boiling mixtures and/or absorbents, colorants, flavoring agents, and sweetening agents.
- a binder such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine,
- the present invention provides a health functional food for the prevention or improvement of cancer containing the compound represented by Chemical Formula 1, its isomer, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the cancer is pseudomyxoma, intrahepatic biliary tract cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, cleft lip cancer, mycosis fungoides, acute myelogenous leukemia, acute lymphocytic leukemia, basal cell cancer, Ovarian epithelial cancer, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colon cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, barter bulge cancer, bladder cancer, peritoneal cancer , Parathyroid cancer, adrenal cancer, non-sinus cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer,
- the compound represented by Formula 1 according to the present invention is a health functional food composition for the prevention or improvement of cancer, in particular, cancer in which EGFR mutation is expressed, by showing a high inhibitory ability against EGFR mutation. Can be added to.
- the compound represented by Formula 1 according to the present invention may be added to food as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement).
- the amount of the compound in the health food may be added in an amount of 0.1 to 90 parts by weight of the total food weight.
- the amount may be less than the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range.
- the health functional beverage composition of the present invention is not particularly limited to other ingredients other than containing the compound as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates, etc. as additional ingredients, as in ordinary beverages.
- natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents tacmatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)
- synthetic flavoring agents sacharin, aspartame, etc.
- the proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 g of the composition of the present invention.
- the compound represented by Chemical Formula 1 according to the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and heavy weight agents (cheese, chocolate, etc.), pects. Acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like.
- the compound represented by Chemical Formula 1 of the present invention may contain flesh for the manufacture of natural fruit juice and fruit juice beverages and vegetable beverages.
- the present invention provides a pharmaceutical composition for preventing or treating diseases related to EGFR mutations containing the compound represented by Formula 1, isomers thereof, or pharmaceutically acceptable salts thereof as an active ingredient.
- the EGFR mutation-related disease may be at least one selected from the group consisting of cancer, psoriasis, eczema, atherosclerosis, stomatous rash, dry skin, chronic diarrhea, liver cirrhosis, myocardial fibrosis, and chronic renal failure.
- the present invention is a cancer or EGFR mutation-related disease comprising the step of administering to a subject in need a pharmaceutical composition or a dietary supplement composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient It provides a method of preventing or treating.
- the present invention provides a use of a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof in the prevention or treatment of cancer or EGFR mutation-related diseases. .
- N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)methanesulfonamide was prepared through the method represented by Scheme 2 below.
- the organic layer was washed with water, brine, dried over Na 2 SO 4 and evaporated under reduced pressure.
- the obtained crude was dissolved in methanol (50 mL), K 2 CO 3 (2.0 g) was added, and stirred for 12 hours. The stirred liquid was evaporated under reduced pressure. Subsequently, the obtained stock solution was diluted with H 2 O (100 mL) and extracted with DCM (100 mL). The aqueous layer was separated, acidified with 1N HCl (pH ⁇ 5-4), and extracted with DCM.
- the product stock solution was purified by flash silica chromatography, and was eluted with DCM containing 1 to 10% MeOH. The pure fractions were evaporated and dried to obtain 4-fluoro-2-methoxy-5-nitroaniline (4.5 g, 76% yield, yellow solid).
- Step 2 Preparation of tert-butyl (4-fluoro-2-methoxy-5-nitrophenyl) carbamate
- the obtained stock solution was purified using column chromatography in which the eluent was hexanes/ethyl acetate (7:3), and tert-butyl (4-fluoro-2-methoxy -5-nitrophenyl)carbamate (4.0 g, 58% yield, yellow solid) was obtained.
- N-(5-amino-2((2-(dimethylamino)ethyl(methyl)amino)-4-methoxyphenyl)acrylamide was prepared through the method represented by Scheme 4 below.
- Step 1 Preparation of tert-butyl (4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5-nitrophenyl)carbamate
- the tert-butyl (4-fluoro-2-methoxy-5-nitrophenyl) carbamate (300 mg, 1.04 mmol) prepared in Preparation Example 1-2 was dissolved in DMF (5 mL) and added to the stirred solution.
- N 1 ,N 1 ,N 2 -Trimethylethane-1,2-diamine (106 mg, 1.04 mmol) and cesium carbonate (183 mg, 1.56 mmol) were added at room temperature.
- the reaction mixture was stirred at 70° C. overnight. Thereafter, the reaction mixture was cooled to room temperature and quenched with ice water.
- Step 2 Preparation of tert-butyl(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)carbamate
- Step 3 Preparation of tert-butyl (5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)carbamate
- Step 4 Preparation of N-(5-amino-2((2-(dimethylamino)ethyl(methyl)amino)-4-methoxyphenyl)acrylamide
- Step 4 of Preparation Example 1-3 except that tert-butyl (5-acrylamido-2-methoxy-4-morpholinophenyl) carbamate prepared in Preparation Example 4-1 was used as a precursor. According to the following, N-(5-amino-4-methoxy-2-morpholinophenyl)acrylamide was prepared.
- Steps 1 to 3 of Preparation Example 1-3 except that N-methyl-2-morpholinoethan-1-amine was used instead of N 1 ,N 1 ,N 2 -trimethylethane-1,2-diamine According to the following, tert-butyl (5-acrylamido-2-methoxy-4-(methyl(2-morpholinoethyl)amino)phenyl)carbamate (69% yield) was prepared.
- N-5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino-2-((2- (Dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide was prepared in the same manner as shown in Scheme 5 below.
- N-(5-amino-2((2-(dimethylamino)ethyl(methyl)amino)-4-methoxyphenyl)acrylic prepared in Preparation Example 1-3 above in a solution dissolved in (30 mL) and stirred Amide (71.5 mg, 0.3 mmol) was added at room temperature The reaction tube was sealed with a Teflon-lined cap, and the reaction mixture was stirred overnight at 90° C.
- the pyrimidine derivative compound according to the present invention N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-2-(4 -(Dimethylamino)piperidin-1-yl)-4-methoxyphenyl)acrylamide, prepared in Preparation Example 2-2, N-(5-amino-2-(4-(dimethylamino)pi) It was prepared according to Example 1, except that peridin-1-yl)-4-methoxyphenyl)acrylamide was used (yield 27%).
- N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy -2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)acrylamide was prepared in Preparation Example 3-2. It was prepared according to Example 1, except that oxy-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)acrylamide was used (yield 30%).
- the pyrimidine derivative compound according to the present invention N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy -2-morpholinophenyl)acrylamide, except that the N-(5-amino-4-methoxy-2-morpholinophenyl)acrylamide prepared in Preparation Example 4-2 was used. It was prepared according to Example 1 (yield 31%).
- the pyrimidine derivative compound according to the present invention N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy -2-(4-methylpiperazin-1-yl)phenyl)acrylamide, prepared in Preparation Example 5-2, N-(5-amino-4-methoxy-2-(4-methylpiperazine-) It was prepared according to Example 1, except that 1-yl)phenyl)acrylamide was used (yield 41%).
- the pyrimidine derivative compound according to the present invention N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-2-(2 -(Dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide, prepared in Preparation Example 6-2, N-(5-amino-2-(2-(dimethylamino)ethoxy)-4- It was prepared according to Example 1 except for methoxyphenyl)acrylamide (yield 29%).
- N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy -2-(methyl(2-morpholinoethyl)amino)phenyl)acrylamide was prepared in Preparation Example 7-2 above. N-(5-amino-4-methoxy-2-(2-morpholino) It was prepared according to Example 1, except that ethoxy)phenyl)acrylamide was used (yield 22%).
- N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy -2-(Methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)phenyl)acrylamide was prepared in Preparation Example 8-2 above N-(5-amino-4-methoxy- It was prepared according to Example 1, except that 2-(methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)phenyl)acrylamide was used (yield 27%).
- the pyrimidine derivative compound according to the present invention N-(5-((5-chloro-4-((2-(methylsulfonamido)phenyl)amido)pyrimidin-2-yl)amino)-4-me N-(5-amino-4-methoxy-2-(methyl(2-morpholino) prepared in Preparation Example 9-2) of oxy-2-(2-morpholinoethoxy)phenyl)acrylamide It was prepared according to Example 1, except that ethyl) amino) phenyl) acrylamide was used (yield 26%).
- the activity measurement for wild-type and EGFR mutant enzymes for the compounds of the present invention was tested as follows using the HTRF system sold by Cisbio. EGFR wild-type and EGFR del19/T790M mutant enzymes were used by purchasing a recombinant protein provided by Carna Biosciences.
- the composition of the assay buffer used for the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl 2 , 3 mM KCl, 0.01% Tween 20, 0.1% BSA, and 1 mM DTT.
- the enzyme reaction was carried out using a peptide substrate labeled with 50 mM ATP and 0.5 mM biotin.
- the analysis of the EGFR activity inhibitory effect of the compound was performed according to the following analytical reaction recipe.
- Component 1 4 mL of EGFR wild-type or mutant enzyme
- Component 3 4 mL ATP and biotin-labeled peptide
- Enzymatic reaction starts by mixing component 1 and component 2 first, and then adding component 3 to it. After 2 hours reaction at 37°C, 10 mL of a measurement solution consisting of streptavidin-XL665 and europium-labeled anti-phosphotyrosine antibody provided by Cisbio was added to the enzyme reaction solution and reacted at room temperature for 1 hour. Finally, the ratio of fluorescence values at 615 nm and 665 nm is calculated using Perkin-Elmer's Envision equipment, and the enzyme activity is quantitatively measured and the inhibitory ability of the compound is confirmed. The measured values measured at the concentrations of the seven compounds were analyzed using the Prism program (version 5.01, Graphpad Software, Inc.), and the IC 50 value, an index of the inhibitory ability of the compound, was calculated.
- All the compounds of the present invention exhibit a relatively weak EGFR activity inhibitory effect against wild-type EGFR, and selectively exhibit high inhibitory ability against EGFR mutations, which is similar to the case of osimertinib, a conventional EGFR tyrosine kinase inhibitor (TKI) drug. Similar things were confirmed.
- TKI EGFR tyrosine kinase inhibitor
- the pyrimidine derivative compound according to the present invention can effectively inhibit the EGFR mutation, and thus can be usefully used as a pharmaceutical composition for preventing or treating cancer.
- the /C797S mutant cell line was used by purchasing a cell line provided by Crown Bioscience.
- the /C797S mutant cell line was cultured in an RPMI containing 10% FBS and 1% penicillin-streptomycin with 1 ug of puromycine in an incubator at 37°C and 5% CO 2.
- 2500 cells/90 ⁇ L were cultured by passage in a 96 well cell culture plate, and after 24 hours, the compound represented by Formula 1 was treated with 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 ( ⁇ M). After the reaction for 72 hours, the plate treated with the compound was allowed to stand at room temperature for 30 minutes, and then 100 ⁇ L of the reagent was further treated and shaking at room temperature for 10 minutes. Finally, the ratio of the fluorescence value at 570 nm is calculated using an equipment, and the quantitative measurement is performed, and the ability of the compound to inhibit cell growth is confirmed. The measured values measured at the concentrations of the 8 compounds were analyzed using the Prism program (version 5.01, Graphpad Software, Inc.), and the IC 50 value, an indicator of the cell growth inhibitory ability of the compound, was calculated.
- All the compounds of the present invention exhibited relatively weak inhibitory effect against wild-type EGFR in Ba/F3 cell lines, and selectively against EGFR mutations including triple mutations EGFR del19/T790M/C797S, EGFR L858R/T790M/C797S. It showed high cell growth inhibitory ability, and was found to be particularly superior to the case of osimertinib, an existing EGFR TKI drug.
- the pyrimidine derivative compound according to the present invention can effectively inhibit the EGFR mutation, and thus can be usefully used as a pharmaceutical composition for preventing or treating cancer.
- Example 1 In order to confirm the ability of the compound represented by Example 1 according to the present invention to inhibit cell growth against the Ba/F3 EGFR exon20 insertion mutation in the Ba/F3 cell line, the following experiment was performed. The results are shown in Table 5 below.
- the activity measurement of the mutant Ba/F3 EGFR cell line for the compound of the present invention was tested as follows using the CellTiter-Glo system sold by Promega.
- CellTiter-Glo assay is a method to check cell viability by measuring ATP present in cells in the cell culture state.
- Ba/F3 EGFR D770delinsGY, H773_V774insH, Y764_V765insHH, V769_D770insASV, D770_N771insSVD mutant cell lines were purchased and used in Pasi A Janne laboratory of Dana-Farber Cancer Institute.
- Ba/F3 D770delinsGY, H773_V774insH, Y764_V765insHH, V769_D770insASV, D770_N771insSVD mutant cell lines were cultured in an incubator at 37° C., 5% CO 2 by adding 1 ⁇ g/ml of puromycine to RPMI containing 10% FBS and 1% penicillin-streptomycin.
- Ba/F3 EGFR V769_D770insASV IC 50 ( ⁇ M) Ba/F3 EGFR D770delinsGY IC 50 ( ⁇ M) Ba/F3 EGFR H773_V774insH IC 50 ( ⁇ M) Ba/F3 EGFR Y764_V765insHH IC 50 ( ⁇ M) Ba/F3 EGFR D770_N771insSVD IC 50 ( ⁇ M) Osimertinib 0.124 0.159 0.191 0.136 0.149 Example 1 0.026 0.021 0.06 0.029 0.027
- the compound represented by Example 1 according to the present invention exhibits high cell growth inhibitory ability against Ba/F3 EGFR exon20 insertion mutations in Ba/F3 cell lines, which is the case of osimertinib, an existing EGFR tyrosine kinase inhibitor (TKI) drug. It was confirmed that it is more excellent.
- TKI EGFR tyrosine kinase inhibitor
- the pyrimidine derivative compound according to the present invention can effectively inhibit the EGFR mutation, and thus can be usefully used as a pharmaceutical composition for preventing or treating cancer.
- the above ingredients were mixed and filled in an airtight cloth to prepare a powder.
- tablets were prepared by tableting according to a conventional tablet preparation method.
- a gelatin capsule was filled according to a conventional capsule preparation method to prepare a capsule.
- injections were prepared by containing the above ingredients in the indicated amount.
- the ingredients suitable for health food are mixed and formulated as a preferred formulation example, but the mixing ratio may be arbitrarily modified.
- the resulting solution After mixing the above ingredients according to a conventional health drink manufacturing method, after stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized container, sealed and sterilized, and then stored in a refrigerator. It was used in preparation.
- composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un dérivé de pyrimidine, un procédé de préparation de celui-ci, et une composition pharmaceutique pour prévenir ou traiter le cancer, comprenant le dérivé de pyrimidine en tant que composant actif, le dérivé présentant un effet inhibiteur relativement faible sur l'activité de l'EGFR par rapport à l'EGFR de type sauvage tout en présentant un effet inhibiteur élevé vis-à-vis des mutations de l'EGFR, et peut ainsi être utilisé de manière efficace pour le traitement du cancer ayant des mutations de l'EGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0130157 | 2019-10-18 | ||
KR1020190130157A KR102383200B1 (ko) | 2019-10-18 | 2019-10-18 | 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021075691A1 true WO2021075691A1 (fr) | 2021-04-22 |
Family
ID=75537846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/010657 WO2021075691A1 (fr) | 2019-10-18 | 2020-08-12 | Dérivé de pyrimidine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que composant actif |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102383200B1 (fr) |
WO (1) | WO2021075691A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4371983A1 (fr) * | 2021-07-13 | 2024-05-22 | Korea Research Institute of Chemical Technology | Nouveaux dérivés de pyrimidine-2,4-diamine, leur procédé de préparation et composition pharmaceutique les contenant en tant que principe actif pour la prévention ou le traitement du cancer |
CA3228333A1 (fr) * | 2021-08-05 | 2023-02-09 | Korea Research Institute Of Chemical Technology | Derive de pyrimidine, son procede de preparation et composition pharmaceutique pour prevenir ou traiter le cancer le comprenant en tant que principe actif |
KR102611488B1 (ko) * | 2021-08-05 | 2023-12-11 | 한국화학연구원 | 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
WO2023063751A1 (fr) * | 2021-10-15 | 2023-04-20 | 제이투에이치바이오텍 주식회사 | Composés inhibant les kinases de mutation alk et/ou egfr et leur utilisation médicale |
WO2023163527A1 (fr) * | 2022-02-23 | 2023-08-31 | 주식회사 카나프테라퓨틱스 | Nouveau composé ayant une activité inhibitrice contre la tyrosine kinase du récepteur du facteur de croissance épidermique, et ses utilisations |
KR102524856B1 (ko) * | 2022-06-23 | 2023-04-24 | 주식회사 카나프테라퓨틱스 | 표피 성장인자 수용체 티로신 키나제에 대한 억제 활성을 갖는 신규 화합물 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105503827A (zh) * | 2014-10-11 | 2016-04-20 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
WO2017101803A1 (fr) * | 2015-12-15 | 2017-06-22 | 合肥中科普瑞昇生物医药科技有限公司 | Nouveau double inhibiteur de egfr et de alk |
KR20170118681A (ko) * | 2014-10-11 | 2017-10-25 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | Egfr 억제제, 및 이의 제조 및 적용 |
KR20190108079A (ko) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2019
- 2019-10-18 KR KR1020190130157A patent/KR102383200B1/ko active IP Right Grant
-
2020
- 2020-08-12 WO PCT/KR2020/010657 patent/WO2021075691A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105503827A (zh) * | 2014-10-11 | 2016-04-20 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
KR20170118681A (ko) * | 2014-10-11 | 2017-10-25 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | Egfr 억제제, 및 이의 제조 및 적용 |
CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
WO2017101803A1 (fr) * | 2015-12-15 | 2017-06-22 | 合肥中科普瑞昇生物医药科技有限公司 | Nouveau double inhibiteur de egfr et de alk |
KR20190108079A (ko) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR102383200B1 (ko) | 2022-04-06 |
KR20210046914A (ko) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021075691A1 (fr) | Dérivé de pyrimidine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que composant actif | |
WO2018230934A1 (fr) | Dérivé de n2,n4-diphénylpyrimidine-2,4-diamine, son procédé de préparation, et composition pharmaceutique le contenant comme principe actif pour la prévention ou le traitement du cancer | |
WO2019112344A1 (fr) | Nouveau dérivé de pyrimidine ayant pour effet d'inhiber la croissance de cellules cancéreuses, et composition pharmaceutique contenant celui-ci | |
WO2018139903A1 (fr) | Composé pyrimidine et son utilisation pharmaceutique | |
WO2018012907A1 (fr) | Nouveaux dérivés de quinazolinone inhibant la pi3k et composition pharmaceutique en contenant | |
WO2020171499A1 (fr) | Nouveau dérivé de pyrido[3,4-d]pyrimidin-8-one ayant une activité inhibitrice de protéine kinase, et composition pharmaceutique pour prévenir, soulager ou traiter le cancer, comprenant celui-ci | |
WO2009125923A2 (fr) | Nouveaux dérivés de bispyridyl carboxamide d'acide indole carboxylique, leurs sels pharmaceutiquement acceptables, procédé de préparation et composition les contenant en tant d'ingrédient actif | |
WO2018088749A1 (fr) | Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires | |
WO2017142325A1 (fr) | Nouveau composé thiophène substitué en 2,3,5 utilisé en tant qu'inhibiteur de la protéine kinase | |
WO2018155947A1 (fr) | Composition pharmaceutique comprenant un composé apte à traverser la barrière hémato-encéphalique en tant que principe actif pour prévenir ou traiter le cancer du cerveau | |
WO2018004258A1 (fr) | Nouveau dérivé hétérocyclique et son utilisation | |
WO2020149715A1 (fr) | Dérivé de pyrrolopyridine et son utilisation dans la prévention et le traitement d'une maladie liée à la protéine kinase | |
WO2021145521A1 (fr) | Dérivé de pyrido[3,4-d]pyrimidine et composition pharmaceutique thérapeutique le comprenant | |
WO2021125803A1 (fr) | Nouveau dérivé de pyrimidine et utilisation correspondante | |
WO2018004213A1 (fr) | Nouveau composé ayant une activité inhibitrice de smo et composition comprenant celui-ci en tant qu'ingrédient actif pour prévenir ou traiter le cancer | |
WO2014109530A1 (fr) | Dérivé 2-(phényléthynyl)thiéno[3,4-b]pyrazine, et composition pharmaceutique comprenant ce dérivé et destinée à la prévention ou au traitement du cancer | |
WO2020040582A1 (fr) | Nouveau dérivé de benzopyrane ou sel pharmaceutiquement acceptable de celui-ci et composition pharmaceutique le comprenant en tant que principe actif | |
WO2020036386A1 (fr) | Dérivé d'isoindolin-1-one, procédé de préparation de celui-ci, et composition pharmaceutique le contenant en tant que composant actif pour la prévention ou le traitement du cancer | |
AU2017256488B2 (en) | Quinazoline derivative or its salt and pharmaceutical composition comprising the same | |
WO2022234965A1 (fr) | Dérivé hétéroaryle, son procédé de préparation et composition pharmaceutique le comprenant en tant que principe actif | |
WO2023287130A1 (fr) | Nouveaux dérivés de pyrimidine-2,4-diamine, leur procédé de préparation et composition pharmaceutique les contenant en tant que principe actif pour la prévention ou le traitement du cancer | |
WO2018056621A1 (fr) | Nouveau dérivé de pyrimidine imidazolyle, son procédé de préparation et une composition pharmaceutique le contenant en tant que principe actif pour prévenir ou traiter le cancer | |
WO2018021826A1 (fr) | Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif | |
WO2021096112A1 (fr) | Dérivé de composé pyrrolopyrimidine, pyrrolopyridine et d'indazole, et composition pharmaceutique thérapeutique le contenant | |
WO2016093554A2 (fr) | Nouveau dérivé de 4-(aryl)-n-(2-alkoxythiéno[3,2-b]pyrazin-3-yl)-pipérazine-1-carboxamide et effet antiprolifératif de celui-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20876928 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20876928 Country of ref document: EP Kind code of ref document: A1 |